Viriom Inc., a San Diego, CA-baed late-stage biotech company developing novel and affordable therapies against life threatening infections, raised $4.7m in equity and non-equity financing.
The round included a three-year grant of $2.35m from The Skolkovo Foundation, for the development of fixed-dose combinations and long-acting injection formulations of Elpida® (elpivirine), the company’s non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV/AIDS.
ChemRar and Torrey Pines Investment committed to this program on a pari passu basis and will provide matching funding in the form of capital investment.
Viriom is a late-stage biotech company developing, manufacturing and distributing novel and affordable therapies against life threatening infections such as HIV and HBV (Hepatitis B virus).
The company has an exclusive worldwide license to its Phase 2-3 HIV oral treatment Elpida® (elpivirine) from F. Hoffmann-La Roche and is developing a proprietary treatment for chronic HBV.